BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions. Comment on Józwiak et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. <i>Pharmaceuticals</i> 2025, <i>18</i>, 185.
Sikiric. Predrag P; Seiwerth. Sven S; Skrtic. Anita A; Staresinic. Mario M; Strbe. Sanja S; Vuksic. Antonia A; Sikiric. Suncana S; Bekic. Dinko D; Soldo. Dragan D; Grizelj. Boris B; Novosel. Luka L; Beketic Oreskovic. Lidija L; Oreskovic. Ivana I; Stupnisek. Mirjana M; Boban Blagaic. Alenka A; Dobric. Ivan I
Key Findings
- BPC‑157 showed no lethal dose in animal studies (LD1 not reached), indicating high safety.
- In mouse and rat models, the peptide reduced Parkinson‑like and Alzheimer‑like brain damage.
- It appears to control angiogenesis and nitric‑oxide levels without promoting tumor growth, and may even have anti‑tumor activity.
Practical Outcomes
- For biohackers, BPC‑157 looks promising as a general healing and neuro‑protective agent, but the abstract provides no specific dosing or administration protocol. Its safety profile suggests it could be tried at low microgram doses used in other anecdotal reports, while monitoring for any unexpected effects. More human data are needed before it can be recommended for serious disease prevention or treatment.
Summary
The paper argues that BPC‑157 is a very safe peptide that helps the body heal by balancing blood‑vessel growth and nitric‑oxide activity. It says the peptide can protect nerves in animal models of Parkinson’s and Alzheimer’s, and even shows anti‑cancer effects, while not causing harmful new blood‑vessel growth.
Abstract
The healing issue is a central, not completely understood, problem in pharmacology, approached by many concepts. One of the most well-known is Robert's and Szabo's concept of cytoprotection, which holds innate cell (epithelial (Robert), endothelial (Szabo)) integrity, protection/maintenance/reestablishing in the stomach to be translated to other organ therapy (cytoprotection→organoprotection) via cytoprotection agent's effect. Thereby, we defend stable gastric pentadecapeptide BPC 157 therapy, efficacy, pleiotropic beneficial effects along with high safety (LD1 not achieved) against Józwiak and collaborators' review speculating its negative impact, speculation of angiogenesis toward tumorogenesis, increased NO and eNOS, toward damaging free radicals formation, and neurodegenerative diseases (Parkinson's disease and Alzheimer's disease). Contrarily, in wound healing and general healing capabilities as reviewed, as a cytoprotective agent, and native cytoprotection mediator, BPC 157 controls angiogenesis and the NO-system healing functions, and counteracts the pathological presentation of neurodegenerative diseases in acknowledged animal models (i.e., Parkinson's disease and Alzheimer's disease), and presents prominent anti-tumor potential, in vivo and in vitro. BPC 157 resolved cornea transparency maintenance, cornea healing "angiogenic privilege" (vs. angiogenesis/neovascularization/tumorogenesis), does not produce corneal neovascularization, but rather opposes it, and per Folkman's concept, it demonstrates anti-tumor effect in vivo and in vitro. BPC 157 exhibits a distinctive effect on NO-level (increase vs. decrease), always combined with counteraction of free radicals formation, and in mice and rats, BPC 157 therapy counteracts Parkinson's disease-like and Alzheimer's disease-like disturbances. Thus, BPC 157 therapy means targeting angiogenesis and NO's cytotoxic and damaging actions, but maintaining, promoting, or recovering their essential protective functions.
Study Information
pubmed
2025
2025-09-28T00:00:00.000Z
10.3390/ph18101450